Tower Research Capital (TRC)’s Endocyte, Inc. Common Stock ECYT Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2018
Q4 | – | Sell |
-8,120
| Closed | -$144K | – | 4730 |
|
|
2018
Q3 | $144K | Buy |
8,120
+7,974
| +5,462% | +$137K | 0.01% | 1156 |
|
|
2018
Q2 | $2K | Sell |
146
-16,197
| -99% | -$192K | ﹤0.01% | 3432 |
|
|
2018
Q1 | $149K | Buy |
16,343
+15,433
| +1,696% | +$85.1K | 0.01% | 1031 |
|
|
2017
Q4 | $4K | Buy |
+910
| New | +$4.33K | ﹤0.01% | 3038 |
|
|
2017
Q3 | – | Sell |
-23,841
| Closed | -$33.2K | – | 4367 |
|
|
2017
Q2 | $36K | Buy |
+23,841
| New | +$51.2K | ﹤0.01% | 920 |
|
|
2017
Q1 | – | Sell |
-100
| Closed | – | – | 4395 |
|
|
2016
Q4 | $0 | Buy |
+100
| New | +$287 | ﹤0.01% | 4758 |
|
|
2016
Q3 | – | Sell |
-4,466
| Closed | -$15K | – | 4976 |
|
|
2016
Q2 | $15K | Buy |
4,466
+2,810
| +170% | +$10.3K | ﹤0.01% | 2504 |
|
|
2016
Q1 | $5K | Buy |
1,656
+1,532
| +1,235% | +$5K | ﹤0.01% | 2801 |
|
|
2015
Q4 | $0 | Sell |
124
-9,014
| -99% | -$41.5K | ﹤0.01% | 5409 |
|
|
2015
Q3 | $42K | Buy |
9,138
+2,520
| +38% | +$13.2K | ﹤0.01% | 1151 |
|
|
2015
Q2 | $35K | Buy |
+6,618
| New | +$39.7K | ﹤0.01% | 1647 |
|
|
2015
Q1 | – | Sell |
-1,155
| Closed | -$7K | – | 5220 |
|
|
2014
Q4 | $7K | Sell |
1,155
-2,948
| -72% | -$18K | ﹤0.01% | 2503 |
|
|
2014
Q3 | $25K | Buy |
4,103
+3,653
| +812% | +$24.9K | ﹤0.01% | 2132 |
|
|
2014
Q2 | $3K | Sell |
450
-2,209
| -83% | -$24.9K | ﹤0.01% | 3280 |
|
|
2014
Q1 | $64K | Buy |
2,659
+754
| +40% | +$10.9K | 0.01% | 921 |
|
|
2013
Q4 | $21K | Sell |
1,905
-2,112
| -53% | -$23.3K | ﹤0.01% | 2303 |
|
|
2013
Q3 | $54K | Buy |
+4,017
| New | +$63.5K | 0.01% | 1847 |
|
Other funds holding ECYT
Tower Research Capital (TRC)'s ECYT Position: Q4 2018 in Review
Tower Research Capital (TRC) sold out of Endocyte, Inc. Common Stock (ECYT) in Q4 2018, closing a stake of 8,120 shares — an estimated $144K sold.
Tower Research Capital (TRC) first reported a position in ECYT in Q3 2013 and held it in 17 quarters. The position peaked at $149K in Q1 2018. 2 funds tracked by Wall St. Rank hold ECYT as of Q4 2018.
- Tower Research Capital (TRC) reported no remaining Endocyte, Inc. Common Stock position as of Q4 2018 after selling out during the quarter.
- Tower Research Capital (TRC) sold 8,120 Endocyte, Inc. Common Stock shares in Q4 2018, an estimated $144K.
- Tower Research Capital (TRC) first reported a position in Endocyte, Inc. Common Stock in Q3 2013 and held it in 17 quarters.
- Tower Research Capital (TRC)'s Endocyte, Inc. Common Stock position peaked at $149K in Q1 2018.
- 2 funds tracked by Wall St. Rank held Endocyte, Inc. Common Stock as of Q4 2018.
Based on Tower Research Capital (TRC)'s 13F filing for Q4 2018, filed 14 Feb 2019.